Hot Topics: Label Expansion in Rheumatoid Arthritis.
By Natasha Spiller, Analyst
28 October 2014
I am an Analyst at Datamonitor Healthcare. After joining the company in 2012, I have produced analysis across a number o...
Read full bio
An important lifecycle management strategy in the rheumatoid arthritis field is the expansion of product labels into juvenile idiopathic arthritis (JIA). Datamonitor Healthcare analyst Natasha Spiller has investigated this hot topic in our latest report.
How will our “Label Expansion: Rheumatoid Arthritis to Juvenile Idiopathic Arthritis” report benefit you?
- Broaden your patient potential
Use our report to understand how companies have extended their drugs’ exclusivity in rheumatoid arthritis through JIA, allowing you to broaden your patient potential by optimizing your development strategies.
- Parallel your own trial designs
Study how Orencia’s late-stage clinical study serves as an ideal case study for trial designs in JIA and use this information to benchmark your own trial designs.
- Gain competitive insight
Understand which candidates are being investigated for potential label expansion to include JIA populations and why others have failed, allowing you to understand the competitive landscape in this field.
Key questions answered
- What incentives across each specific region are available for companies that expand their labels successfully into JIA?
- How are DMARDs positioned in the JIA market?
- Why did Remicade, Kineret, and Simponi fail to achieve label expansion into JIA?
Posted in Immunology and Inflammation.